Sabra Healthcare Reit Stock Alpha and Beta Analysis
| SBRA Stock | USD 17.54 0.16 0.92% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Sabra Healthcare REIT. It also helps investors analyze the systematic and unsystematic risks associated with investing in Sabra Healthcare over a specified time horizon. Remember, high Sabra Healthcare's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Sabra Healthcare's market risk premium analysis include:
Beta 0.54 | Alpha 0.11 | Risk 1.66 | Sharpe Ratio 0.0541 | Expected Return 0.0899 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Sabra |
Sabra Healthcare Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Sabra Healthcare market risk premium is the additional return an investor will receive from holding Sabra Healthcare long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Sabra Healthcare. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Sabra Healthcare's performance over market.| α | 0.11 | β | 0.54 |
Sabra Healthcare expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Sabra Healthcare's Buy-and-hold return. Our buy-and-hold chart shows how Sabra Healthcare performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Sabra Healthcare Market Price Analysis
Market price analysis indicators help investors to evaluate how Sabra Healthcare stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Sabra Healthcare shares will generate the highest return on investment. By understating and applying Sabra Healthcare stock market price indicators, traders can identify Sabra Healthcare position entry and exit signals to maximize returns.
Sabra Healthcare Return and Market Media
The median price of Sabra Healthcare for the period between Mon, Dec 30, 2024 and Sun, Mar 30, 2025 is 16.62 with a coefficient of variation of 2.53. The daily time series for the period is distributed with a sample standard deviation of 0.42, arithmetic mean of 16.71, and mean deviation of 0.33. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Richard Matros of 14317 shares of Sabra Healthcare subject to Rule 16b-3 | 01/06/2025 |
2 | Acquisition by Richard Matros of 285144 shares of Sabra Healthcare subject to Rule 16b-3 | 01/15/2025 |
3 | SoftBank Robotics America receives Platinum Service Elite certification from Gausium | 01/23/2025 |
4 | Acquisition by Malehorn Jeffrey A. of 826 shares of Sabra Healthcare subject to Rule 16b-3 | 01/31/2025 |
5 | Acquisition by Porter Clifton J Ii of 798 shares of Sabra Healthcare subject to Rule 16b-3 | 02/06/2025 |
6 | Head-To-Head Analysis American Tower versus Sabra Health Care REIT | 02/10/2025 |
7 | Sabra Reports Fourth Quarter 2024 Results Introduces 2025 Guidance | 02/19/2025 |
8 | Acquisition by Cusack Catherine of 1500 shares of Sabra Healthcare at 15.92 subject to Rule 16b-3 | 02/24/2025 |
9 | Insider Buying Catherine Cusack Acquires Shares in Sabra Health Care REIT Inc | 02/26/2025 |
10 | Acquisition by Richard Matros of 14676 shares of Sabra Healthcare subject to Rule 16b-3 | 02/28/2025 |
11 | Sabra Health Care REIT, Inc. Receives Consensus Rating of Moderate Buy from Analysts | 03/04/2025 |
12 | Prologis Gains 17.4 percent Year to Date Will It Continue to Rise | 03/06/2025 |
13 | Edgestream Partners L.P. Acquires Shares of 149,700 Sabra Health Care REIT, Inc. - MarketBeat | 03/10/2025 |
14 | Should You Retain Essex Property Stock in Your Portfolio Now | 03/14/2025 |
15 | Heres Why You Should Add Cousins Properties Stock to Your Portfolio | 03/17/2025 |
16 | Armada Hoffler Secures Three New Office Leases at The Interlock | 03/21/2025 |
17 | Sabra Health Care REIT Inc Announces Leadership Transition | 03/24/2025 |
18 | Sabra Health Care REIT, Inc. to Attend Deutsche Banks 2025 Healthcare REIT Summit | 03/27/2025 |
About Sabra Healthcare Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Sabra or other stocks. Alpha measures the amount that position in Sabra Healthcare REIT has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | |
| Dividend Yield | 0.0965 | 0.0841 | 0.0693 | 0.0646 |
| Price To Sales Ratio | 4.59 | 5.1 | 5.75 | 9.78 |
Sabra Healthcare Upcoming Company Events
As portrayed in its financial statements, the presentation of Sabra Healthcare's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sabra Healthcare's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Sabra Healthcare's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Sabra Healthcare. Please utilize our Beneish M Score to check the likelihood of Sabra Healthcare's management manipulating its earnings.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Sabra Healthcare
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Sabra Healthcare Backtesting, Sabra Healthcare Valuation, Sabra Healthcare Correlation, Sabra Healthcare Hype Analysis, Sabra Healthcare Volatility, Sabra Healthcare History and analyze Sabra Healthcare Performance. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Sabra Healthcare technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.